Shattuck Labs Reports Second Quarter 2024 Financial Results and Recent Business Highlights
01 août 2024 16h05 HE
|
Shattuck Labs, Inc.
– Announced updated positive interim data from the Phase 1B dose-expansion clinical trial of SL-172154 in combination with Azacitidine (AZA) in frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS)...
Shattuck Labs Announces Participation in Upcoming BTIG Virtual Biotechnology Conference
30 juil. 2024 17h00 HE
|
Shattuck Labs, Inc.
AUSTIN, TX and DURHAM, NC, July 30, 2024 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion...
Shattuck Labs Announces Addition to Russell 2000® and Russell 3000® Indexes
01 juil. 2024 06h00 HE
|
Shattuck Labs, Inc.
AUSTIN, TX & DURHAM, NC, July 01, 2024 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (Nasdaq: STTK), a clinical-stage biotechnology company pioneering the development of bifunctional fusion...
Shattuck Labs Announces Updated Positive Interim Data from the Phase 1B Dose Expansion Clinical Trial of SL-172154 in Combination with Azacitidine (AZA) in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) Patients
14 juin 2024 06h00 HE
|
Shattuck Labs, Inc.
– Observed 67% Objective Response Rate (ORR) in frontline HR-MDS patients, primarily with TP53 mutations; initial complete remission (CR)/marrow complete remission (mCR) rate of 58% and median overall...
Shattuck Labs Announces Orphan Drug Designation Granted by the U.S. Food and Drug Administration (FDA) for SL-172154 for the Treatment of Acute Myeloid Leukemia (AML)
10 juin 2024 07h30 HE
|
Shattuck Labs, Inc.
AUSTIN, TX and DURHAM, NC, June 10, 2024 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (Nasdaq: STTK), a clinical-stage biotechnology company pioneering the development of bifunctional fusion...
Shattuck Labs to Host Investor Call and Webcast on Additional Interim Data Presented at the European Hematology Association (EHA) 2024 Congress from the Phase 1B Dose Expansion Clinical Trial of SL-172154 with Azacitidine (AZA) in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) Patients
06 juin 2024 07h30 HE
|
Shattuck Labs, Inc.
- Conference call and webcast to be held June 14, 2024 at 7:30 a.m. ET featuring lead investigator - AUSTIN, TX and DURHAM, NC, June 06, 2024 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck)...
Shattuck Labs to Present Additional Data from the Phase 1B Dose Expansion Clinical Trial of SL-172154 with Azacitidine (AZA) in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) Patients at the European Hematology Association (EHA) 2024 Congress
14 mai 2024 16h15 HE
|
Shattuck Labs, Inc.
– Observed encouraging complete response (CR) rates as of the February 1, 2024, data cutoff in previously untreated HR-MDS and TP53m AML patients; successfully bridged responding TP53m AML patients to...
Shattuck Labs Reports First Quarter 2024 Financial Results and Recent Business Highlights
02 mai 2024 07h05 HE
|
Shattuck Labs, Inc.
- Completed additional enrollment in Phase 1B dose-expansion cohorts for TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) patients in the first quarter of 2024; updated combination data expected at...
Shattuck Labs Announces Oral Presentation of Preclinical Data at the American Association for Cancer Research (AACR) Annual Meeting 2024
09 avr. 2024 16h05 HE
|
Shattuck Labs, Inc.
– Aberrant TRIM7 expression identified as a key driver of immune checkpoint blockade (ICB) acquired resistance; inhibition of TRIM7 with small molecule inhibitors may prevent or reverse acquired...
Shattuck Labs Announces Participation in Upcoming 23rd Annual Needham Virtual Healthcare Conference
01 avr. 2024 07h00 HE
|
Shattuck Labs, Inc.
AUSTIN, TX & DURHAM, NC, April 01, 2024 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional...